| Triple-negative breast cancer: current perspective on the evolving therapeutic landscape J Mehanna, FGH Haddad, R Eid, M Lambertini, HR Kourie International journal of women's health, 431-437, 2019 | 196 | 2019 |
| Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial E Jabbour, NJ Short, N Jain, X Huang, G Montalban-Bravo, P Banerjee, ... The Lancet Haematology 10 (1), e24-e34, 2023 | 161 | 2023 |
| Telemedicine for cancer patients during COVID-19 pandemic: between threats and opportunities R Elkaddoum, FG Haddad, R Eid, HR Kourie Future oncology 16 (18), 1225-1227, 2020 | 128 | 2020 |
| New developments in the management of head and neck cancer–impact of pembrolizumab K Saleh, R Eid, FGH Haddad, N Khalife-Saleh, HR Kourie Therapeutics and clinical risk management, 295-303, 2018 | 83 | 2018 |
| The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades E Jabbour, NJ Short, N Jain, FG Haddad, MA Welch, F Ravandi, ... Journal of Hematology & Oncology 16 (1), 22, 2023 | 75 | 2023 |
| Treatment of adults with Philadelphia chromosome–positive acute lymphoblastic leukemia—from intensive chemotherapy combinations to chemotherapy-free regimens: a review E Jabbour, FG Haddad, NJ Short, H Kantarjian JAMA oncology 8 (9), 1340-1348, 2022 | 73 | 2022 |
| Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements GC Issa, J Zarka, K Sasaki, W Qiao, D Pak, J Ning, NJ Short, F Haddad, ... Blood cancer journal 11 (9), 162, 2021 | 70 | 2021 |
| Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute … E Jabbour, NJ Short, J Senapati, N Jain, X Huang, N Daver, CD DiNardo, ... The Lancet Haematology 10 (6), e433-e444, 2023 | 65 | 2023 |
| Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors FG Haddad, K Sasaki, GC Issa, G Garcia‐Manero, F Ravandi, T Kadia, ... American journal of hematology 97 (7), 856-864, 2022 | 60 | 2022 |
| Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results H Kantarjian, NJ Short, N Jain, K Sasaki, X Huang, FG Haddad, I Khouri, ... American journal of hematology 98 (3), 493-501, 2023 | 59 | 2023 |
| Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1 NJ Short, E Jabbour, W Macaron, F Ravandi, N Jain, ... American journal of hematology 98 (8), 1196-1203, 2023 | 45 | 2023 |
| Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature M Ghosn, HR Kourie, E El Rassy, FG Haddad, C Hanna, F El Karak, ... World journal of gastrointestinal oncology 8 (10), 745, 2016 | 38 | 2016 |
| The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review E Moujaess, FG Haddad, R Eid, HR Kourie Immunotherapy 11 (16), 1409-1422, 2019 | 37 | 2019 |
| Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience G Richard-Carpentier, HM Kantarjian, G Tang, CC Yin, JD Khoury, ... Blood Advances 5 (23), 5415-5419, 2021 | 36 | 2021 |
| Immunotherapy: last bullet in platinum refractory germ cell testicular cancer A Semaan, FGH Haddad, R Eid, HR Kourie, E Nemr Future Oncology 15 (5), 533-541, 2019 | 31 | 2019 |
| ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment? C Hobeika, G Rached, R Eid, F Haddad, S Chucri, HR Kourie, J Kattan Personalized medicine 15 (2), 111-115, 2018 | 31 | 2018 |
| Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia H Kantarjian, FG Haddad, N Jain, K Sasaki, NJ Short, S Loghavi, ... Journal of Hematology & Oncology 16 (1), 44, 2023 | 28 | 2023 |
| Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis E Jabbour, K Sasaki, FG Haddad, GC Issa, J Skinner, S Dellasala, ... American journal of hematology 97 (11), 1413-1418, 2022 | 28 | 2022 |
| EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution experience S Naderi, C Ghorra, F Haddad, HR Kourie, M Rassy, F El Karak, M Ghosn, ... Cancer epidemiology 39 (6), 1099-1102, 2015 | 27 | 2015 |
| Targeting CD47/SIRPα in acute myeloid leukemia and myelodysplastic syndrome: preclinical and clinical developments of magrolimab F Haddad, N Daver Journal of Immunotherapy and Precision Oncology 4 (2), 67, 2021 | 25 | 2021 |
